Orthomolecular Therapy and Down Syndrome: Rationale and Clinical Results | Author article list |
Robert J. Thiel, Ph.D., N.M.D. |
8th Annual Scientific Program of the Orthomolecular Health-Medicine Society March 1, 2002. San Francisco, CA Reprinted with the permission of the author |
INTRODUCTION
Trisomy 21, more commonly referred to as Down syndrome, is a genetic disorder
which is present in approximately 1 out of every 700 live births. It results in
three number 21 chromosomes, as opposed to the normal two [1]. "The diagnostic
clinical features of this condition are usually readily evident, even at birth.
The flat facial profile, oblique palpebral fissures...Down syndrome is a leading
cause of mental retardation. The mental retardation is severe...Virtually all
patients with trisomy 21 older than 40 years of age develop neuropathologic
changes characteristic of Alzheimer's disease, a degenerative disorder of the
brain. Patients with Down syndrome have abnormal immune responses that
predispose them to serious infections, particularly of the lungs, and to thyroid
autoimmunity" [1]. Down's patients tend to be short since at age 18 the median
average female with Down Syndrome grows to approximately 4'9½", and the
average male grows to approximately 5'½" [2]. "These patients also have
immune defects and an increased susceptibility to leukemia...Essentially nothing
is known about how one extra chromosome 21 could have such profound effects"
[3].
While there is no effective medical intervention for trisomy 21, there are treatments for complications such as cardiovascular disorders, hypothyroidism, and infections. Though some recommend nutrition as part of a program for those with trisomy disorders, the prevalent medical opinion appears to be that orthomolecular medicine is ineffective [4,5].
In 1940, Dr. Henry Turkel (M.D.) began experimenting with orthomolecular medicine for Down syndrome [4]. Due to problems with the US FDA, he ended up basically being confined to practicing only in Michigan (as well as Japan). In the mid 1970s, Dr. F. Jack Warner (M.D.) began to communicate with Turkel. In a meeting in California in 1984, Turkel asked Warner to take over his work. Since that time, Warner began to specialize in seeing patients with trisomy 21. Warner has probably seen more people with Down syndrome than any doctor currently living. The mother of one of his patients, Dixie Lawrence, did additional research and developed another formula, originally similar to that which Warner uses, but without iron and L-glutamine, but including certain amino acids. Dr. Lawrence Leichtman (M.D.), with others (including Lawrence), has been working to modify/expand Lawrence's formula. This researcher (Thiel) has made modifications to previous approaches by attempting to better individualize orthomolecular medicine for those with Down syndrome, advocating more natural vitamins/minerals, supporting suspected hypothyroidism nutritionally, and correlating some of the orthomolecular connections between Down syndrome and epilepsy [6,7]. This paper discusses some nutrients used in orthomolecular therapy and some of the results that Warner has attained.
SELECTED NUTRIENTS OF INTEREST
There are any number of nutrients which could be looked into; those shown
below are some of those thought to be of more interest for this paper.
RESULTS
This researcher conducted an investigation of a randomly-selected sample of
Warner's Down syndrome patient files. Height, weight, facial swelling, nose
bridge development, and epicanthal eye fold was examined. The brief results are
shown in the tables below (study details are part of two papers [58-59]):
Gender | N | Attibute | Initial Mean | Final Mean |
---|---|---|---|---|
as Percentile on Down's Grid | ||||
Female | 36 | Height | 63.1% | 73.6% |
Male | 48 | Height | 63.6% | 77.8% |
Total | 84 | Height | 63.4% | 76.0% |
Gender | N | Attibute | Initial Mean | Final Mean |
---|---|---|---|---|
as Percentile on Down's Grid | ||||
Female | 40 | Weight | 60.9% | 59.3% |
Male | 50 | Weight | 45.2% | 53.7% |
Total | 90 | Weight | 52.2% | 56.2% |
For facial appearance, a comparison was made of before and after photographs in Warner's files. A ten point scale was developed with zero signifying normal for children without Down syndrome and to a maximum of ten signifying an appearance consistent with the more pronounced presentation of this feature. For example, a lack of any noticeable (or completely flat) nose bridge would receive a score of 10, whereas a completely normal appearing nose bridge would receive a score of zero. Some data was excluded if it was unclear from the photographs.
Gender | N | Attibute | Initial Mean | Final Mean | Percent Improvement |
---|---|---|---|---|---|
on 10 Point Scale | |||||
Female | 39 | Facial Swelling | 5.9 | 4.2 | 28.8% |
Male | 46 | Facial Swelling | 6.6 | 2.8 | 57.6% |
Total | 85 | Facial Swelling | 6.3 | 3.4 | 46.0% |
Gender | N | Attibute | Initial Mean | Final Mean | Percent Improvement |
---|---|---|---|---|---|
on 10 Point Scale | |||||
Female | 37 | Nose Bridge | 7.8 | 5.1 | 34.6% |
Male | 45 | Nose Bridge | 7.5 | 5.2 | 30.7% |
Total | 82 | Nose Bridge | 7.6 | 5.1 | 32.9% |
Gender | N | Attibute | Initial Mean | Final Mean | Percent Improvement |
---|---|---|---|---|---|
on 10 Point Scale | |||||
Female | 38 | Epicanthal Fold | 5.4 | 3.8 | 29.6% |
Male | 43 | Epicanthal Fold | 6.1 | 4.0 | 34.4% |
Total | 81 | Epicanthal Fold | 5.8 | 3.9 | 32.8% |
DISCUSSION
In spite of apparent nutritional differences and clinical results, the use of
orthomolecular medicine for persons with Down syndrome has been repeatedly
challenged [5,60,61]. However, even some mainstream researchers have recommended
vitamin and mineral supplementation for those with Down syndrome [62,63]. Early
work, done by Turkel [4] as well as a study by Harrell et al [64] concluded that
nutritional intervention did raise intelligence of persons with Down syndrome.
Others, including the American Academy of Pediatrics, have criticized these
researchers and have concluded that nutritional interventions are not effective
[5,59,65]. Yet, Dr. Bernard Rimland (Ph.D.) investigated the work of some of the
critics and found that they do not in fact properly duplicate with the Turkel or
Harrell work; furthermore Rimland has written that the position of the American
Academy of Pediatrics is "inaccurate, biased, and inept" [66]. Turkel, Warner,
and others have shown before and after photographs to demonstrate that
orthomolecular medicine can improve the appearance of those with Down syndrome
[4,48]. This researcher, as shown above, has found that height, as well as
facial features, appear to respond to orthomolecular medicine, specifically the
Warner protocol [58,59]. Napolitano et al found that zinc supplementation
increased growth in 15 of 22 children with Down syndrome [40].
Why might orthomolecular medicine play a role? Aside from the obvious nutritional differences previously mentioned in this paper, there are several possible reasons.
Down syndrome patients have increased incident of thyroid disorders [1,67,68]. Most orthomolecular interventions for it contain iodine which has been shown to be helpful for some thyroid problems [69] as well as the amino acid tyrosine (the primary thyroid hormone is composed of iodine and tyrosine [70]) and the minerals zinc and selenium. Bucci speculated that zinc deficiency may be one cause of subclinical hypothyroidism in children with Down syndrome [39], while a study by Kanavan et al found that thyroid hypofunction in Down syndrome appeared to be partially related to low selenium levels [71].
Phenylketonuria, which can also cause mental retardation, is caused by a deficiency of hepatic phenylalanine hydroxylase and reduces the conversion of phenylalanine into tyrosine, and is often controlled by reducing consumption of high phenylalanine foods [72]; there is a case report where a improvements were noted in a Down's patient who went on a low phenylalanine diet [73]. Since those with Down's tend to have a problem converting phenylalanine into tyrosine [55], it is possible that DYRK (dual-specificity tyrosine-regulated kinase) may have some involvement. DYRK1A, which is located in the Down syndrome critical region of chromosome 21, catalyzes tyrosine directed autophosphorylation as well as the phosphorylation of serine residues--it is suspected that DYRK1A may be involved in causing mental retardation in Down syndrome [74,75]. It should be added that DYRK1A only affects certain tyrosine forms [76]. DYRK1A may not have anything to do directly with the development of hypothyroidism or any other specific tyrosine abnormality currently recognized as being part of Down syndrome, but its impact does show that there are metabolic differences in Down syndrome that affect nutrients somewhat differently than occur in the non-Down's population.
Oxygen radical-induced damage appears to be important in Down's, Alzheimer's, and other illnesses with a neuropsychiatric components [56,77]. Biomarkers of oxidative stress have been found to be significantly elevated in patients with Down syndrome [78,79]. Warner has clinical findings which support his position that ingestion of antioxidant nutrients have the effect of lowering the body's levels of superoxide dismutase [79]--others involved with natural health have suggested that antioxidant nutrients such as vitamin C, beta carotene, flavonoids, zinc, selenium, and vitamin E may reduce free radical damage and possibly slow the accelerated aging associated with Down's [77,80]. Some believe that the impaired viability of Down syndrome neurons can be amended by antioxidants, such as vitamin E [78].
Carnosine is an efficient chelating agent for copper [81] which is of interest as many with DS have abnormally high copper levels [26,29,30]. Carnosine and related compounds such as homocarnosine have been found to have protective effects against hydrogen peroxide-mediated Cu,Zn-superoxide dismutase fragmentation [82] and Cu,Zn-superoxide mutants [83]. Accelerated brain glycation (and the resulting brain damage) occurs early in the life of those with Down syndrome [84]and carnosine is also an antiglycation agent [85,86]. Since selenium rich yeast has been shown to have 123 times the antiglycation effect as sodium selenite for diabetics [87], it may be the preferred form to use when Down syndrome is present.
Supplementation with acetyl-l-carnitine has been shown to improve memory and attention in patients with Down syndrome [88]. N,n-dimethylglycine (DMG), an amino acid derivative, is naturally found in the human body and supports transmethylation processes [89]. There is a report of a Korean study which used DMG for autistic children which found that it improved verbal communications and behavior, while a report of a Taiwanese study suggests that DMG reduced lethargy in autistic children, but did not improve speech [90]--Warner has found that it does improve speech in those with Down syndrome [48]. Down children are especially prone to bacterial respiratory infections [1]. One study found that supplementation with selenium rich yeast tablets significantly stimulated serum concentrations of IgG2 and IgG4 antibodies (which are frequently low in Down syndrome patients) [34]. IgG2 is known to be directed against the bacterial polysaccharide antigens of encapsulated bacteria such as streptococcus pneumoniae and hemophilus influenza [34]. An Italian study, however, found that low levels of vitamin C consumption was correlated with increased infection rates for children with Down syndrome [21]. Warner reports a reduced incidence of infections for those undergoing his treatment [48].
Dietary restrictions may also be advisable. A study involving Dutch children with Down syndrome concluded that those children were more prone to have celiac disease than other Dutch children, but not more likely to have a cow's milk intolerance [91]. Celiac disease seems to increase IgA and IgG in Down's patients [92,93]. A German study concluded that children with Down syndrome had higher bovine serum albumin antibody levels than others [94]. Thiel, Warner, and Leichtman often advise against the consumption of cow's milk for those with Down syndrome, but Turkel did not.
CONCLUSION
Whether or not specifically due to the presence of a third 21st chromosome,
metabolic disturbances are involved with Down syndrome. The nutritional profiles
of the Down syndrome population do in certain significant ways, differ from
those of the general public. Various signs and symptoms associated with Down
syndrome have been reported to improve when certain nutritional protocols have
been tried (and there is no accepted medical treatment currently in existence
for Down syndrome). Orthomolecular medicine has safely been treating people with
Down syndrome for over sixty years. Orthomolecular medicine is a logical therapy
to consider when Down syndrome is present.
REFERENCES
[1] Cotran RS, Kumar V, Collins T. Pathologic Basis of Disease, 6th ed. WB Saunders, Phil., 1999
[2] Van Dyke DC, Lang DJ, Heide F, van Duyne S, Soucek MJ, editors. Standardized anthropometric techniques. In
Clinical Perspectives in the Management of Down Syndrome. Springer-Verlag, NY, 1990:230-237
[3] Kissane JM. Anderson's Pathology, 9th ed. CV Mosby Co., St. Louis, 1990
[4] Turkel H, Nusbaum I. Medical Treatment of Down Syndrome and Genetic Diseases, 4th ed. Ubiotica, Southfield (MI), 1985
[5] Sacks BI, Buckley RF. Multi-nutrient formulas and other substances as therapies for Down syndrome: an overview. Down Syndrome News and Update 1(2):70-83, 1998
[6] Cohen B, Thiel RJ. What to do about borderline elevated TSH levels? Presentation at the Down Syndrome Medical Interest Group, San Diego, July 8, 2001
[7] Thiel RJ. Down syndrome and autism. Presentation at the 20th Annual Convention of the American Naturopathic Medical Association, Las Vegas, November 9, 2001
[8] Baer MT, Waldron J, Gumm H, Van Dyke DC, Chang H. Nutrition assessment of the child with Down syndrome. In Clinical Perspectives in the Management of Down Syndrome. Springer-Verlag, NY, 1990:107-125
[9] Filippello M, Cascone G, Zagami A, Scimone G. Impression cytology in Down's syndrome. Br J Opthalmol,1997;81(8):683-685
[10] Palmer S. Influence of vitamin A nutriture on the immune response: findings in children with Down's syndrome. Int J Vitam Nutr Res 1978;48(2):188-216
[11] Schmid F, Christeller S, Rehm W. Studies on the state of vitamins B1, B2 and B6 in Down's syndrome. Fortschr Med 1975;93(25):1170-1172
[12] Chad K, Jobling A, Frail H. Metabolic rate: a factor of developing obesity in children with Down syndrome? Am J Ment Retard 1990;95(2):228-235
[13] McCoy EE, Columbini C, Ebadi M. The metabolism in vitamin B6 in Down's syndrome. Ann NY Scie 1969;166(1):116-125
[14] Tu JB, Zellweger H. Blood serotinin deficiency in Down's syndrome. Lancet 1965;2(415):715-716
[15] Frager J, Barnet A, Weiss I, Coleman M. A double blind study of vitamin B6 in Down's syndrome infants. J Ment Def Res 1985;29(Pt3):241-246
[16] David O, Fiorucci GC, Tosi MT, Altare F, Valori A, Saracco P, Asinardi P, Ramenghi U, Gabutti V. Hematological studies in children with Down syndrome. Pediatr Hematol Oncol 1996;13(3):271-275
[17] Ibarra B, Rivas F, Medina C, Franco ME, Romero-Garcia F, Enrique C, Galarza M, Hernandez-Cordova A, Hernandez T. Hematological and biochemical studies in
children with Down syndrome. Ann Genet 1990;33(2):84-87
[18] Wachtel TJ, Pueschel SM. Macrocytosis in Down syndrome. Am J Ment Retard
1991;95(4):417-420
[19] Gericke GS, Hesseling PB, Birnk S, Tiedt FC. Leukocyte ultrastructure and folate metabolism in Down's syndrome. S Afr Med J
1977;51(12):369-374
[20] Hestnes A, Stovner LJ, Husoy O, Folling I, Fougner KJ, Sjaastad O. Hormonal and biochemical studies in children with Down's
syndrome. J Ment Defic Res 1991;35 (Pt 3):179-193
[21] Colombo MI, Girdardo E, Incarbone E, Conti R, Ricci BM, Maina D. Vitamin C in children with trisomy 21. Minerva Pediatr,1989;41(4):189-192
[22] Hilty N, Sepp N, Rammal E, Pechlaner C, Hintner H, Fritsch P. Scurvy in trisomy 21. Hautarzt
1991;42(7):464-466
[23] Center J, Beange H, McElduff A. People with mental
retardation have an increased prevalence of osteoporosis. Am J Ment Retard
1998;103(1):19-28
[24] Molteno C, Smit I, Mills J. Huskisson J. Nutritional
status of patients in a long-stay hospital for people with mental handicap. S
Afr Med J 2000;90(11):1135-1140
[25] Cenzig M, Seven M. Vitamin and mineral
status in Down syndrome. Trace Elem Elec 2000;17(1):156-160
[26] Werbach M.
Down syndrome. In Textbook of Nutritional Medicine. Third Line Press, Tarzana
(CA):340-348
[27] McCoy EE, Sneddon JM. Decreased calcium content and 45Ca2+
uptake in Down's syndrome blood platelets. Pediatr Res
1984;18(9):914-916
[28] Barlow PJ, Sylvestrer PE, Dickerson JW. Hair trace
metal levels in Down syndrome patients. J Ment Def Res 1981;25(Pt
3):161-168
[29] Purice M, Maximillan C, Dumitru I, Ioan D. Zinc and copper in
plasma and erythrocytes of Down's syndrome children. Endocrinologie
1988;26(2):113-117
[30] Kadrobova J, Madaric A, Sustrova M, Ginter E.
Changed serum element profile in Down's syndrome. Biol Trace Elem Res
1996;54(3):201-206
[31] Anneren G, Johansson E, Lindu U. Trace element
profiles in individual blood cells from patients with Down's syndrome. Acta
Paediatr Scand 1985;74(2):259-263
[32] Monteiro CP, Varela A, Pinto M, Neves
J, Felisberto GM, Vaz C, Bicho MP, Laires MJ. Effects of an aerobic training
program on magnesium, trace elements and antioxidant systems in Down syndrome
population. Magnes Res 1997;10(1):65-71
[33] Barlow PJ, Sylvestrer PE, Dickerson JW. Hair trace metal levels in Down syndrome patients. J Ment Def Res
1981;25(Pt 3):161-168
[34] Anneren G, Magnusson CG, Nordvall SL. Increase in
serum concentrations of IgG2 and IgG4 by selenium supplementation in children
with Down's syndrome. Arch Dis Child 1990;65(12):1353-1355
[35] Hamilton K.
Down's syndrome: selenium supplementation and trace elements. CP Currents
1994;4(3):46
[36] Kralik A, et al. Influence of zinc and selenium deficiency
on parameters related to thyroid metabolism. Hormone Metabol Res
1996;28:223-226
[37] Sherman AR. Zinc, copper and iron nutriture and
immunity. J Nutr,1992;122:604-609
[38] Stabile A, et al. Immunodeficiency and plasma zinc levels in children with Down's syndrome: a long-term follow-up of oral zinc supplementation. Clin Immunolog Immunopath, 1991;58:207:216
[39] Bucci I, Napolitano G, Giuliani C, Lio S, Minnucci A, Di Giacomo F,
Calabrese G, Sabatino G, Palka G, Monocao F. Zinc sulphate supplementation
improves thyroid hypofunction in hypozincemic Down children. Biol Trace Elem Res 1999;67:257-268
[40] Napolitano G, Plaka G, Grimaldi S, Guilani C, Laglia G, Calabreese G, Satta MA, Neri G, Monaco F. Growth delay in Down syndrome and zinc sulphate supplementation. Amer J Med Genetics 1990;S7:63
[41] Abdallah SM, Samman S. The effect of increasing dietary zinc on the activity of superoxide and dismutase and zinc concentrations in healthy female subjects. Eur J Clin Nutr 1993;47:327-332
[42] Perry EK, Perry RH, Smith CJ, Purohit D, Bonham J, Dick DJ, Candy JM, Edwardson JA, Fairbairn A. Cholinergic receptors in cognitive disorders. Can J Neurol Sci 1986;13(S4):521-527
[43] Cantor DS, et al. A report on phosphatidylcholine therapy in a Down's syndrome child. Psychol Rep 1986;58:207-217
[44] Lejeune J, Rethore MO, de Blois MC, Peeters M, Naffah J, Megarbane A, Cattaneo F, Mircher O, Rabier D, Parvey P, et al. Amino acids and trisomy 21. Ann Genet 1992;35(1):8-13
[45] Lemere CA, et al. The lysomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An imunocytochemical study. Am J Pathol 1995,146(4):848-860
[46] Werbach M. Epilepsy. In Textbook of Nutritional Medicine. Third Line Press, Tarzana (CA), 1999:363-375
[47] Meyers LF. Language development and intervention. In Clinical Perspectives in the Management of Down Syndrome. Springer-Verlag, NY, 1990:153-164
[48] Warner FJ. Nutrition and Down syndrome. Presentation at the Third Annual Convention of the California State Naturopathic Medical Association, Buena Park, February 11, 2001
[49] Shetty HU, Siarey RJ, Galdzicki Z, Stoll J, Rapoport SI. Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-inositol in selected brain regions and regional and peripheral tissues. Neuochem Res 2000;25(4):431-435
[50] Huang W, Alexander GE, Daly EM, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB. High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adult's with Down's syndrome. Am J Psychiatry 1999;156(12):1879-1886
[51] Shonk T, Ross BD. Role of increased cerebral myo-inositol I the dementia of Down syndrome. Magn Reson Med 1995;33(6):858-861
[52] Shetty HU, Schapiro MB, Holloway HW, Rapaport SI. Polyol profiles in Down syndrome: myo-inositol, specifically is elevated in the cerebrospinal fluid. J Clin Invest 1995;95(2):542-546
[53] Hamilton K. Down's syndrome. In Clinical Pearls in Nutrition and Preventative Medicine. ITServices, Sacramento, 1998:204
[54] Watkins SE, Thomas DE, Clifford M, Tidmarsh SF, Sweeney AE. Ah-Sing E, Dickerson JW, Cowie VA, Shaw DM. Plasma amino acids in patients with senile dementia and in subjects with Down's syndrome at an age vulnerable to Alzheimer's changes. J Ment Defic Res 1989;33(Pt 2):159-166
[55] Shaposhnikov AM, Khal'chitskii SE, Shvarts EI. Disorders of phenylalanine and tyrosine metabolism in Down's syndrome. Vopr Med Khim 1979;25(1):15-19
[56] Leichtman LG. Targeted nutritional intervention (TNI) in the treatment of children and adults with Down syndrome. 1998 NDSC Meeting
[57] Airaksinen EM. Tryptophan treatment of infants with Down's syndrome. Ann Clin Res 1974;6(1):33-39
[58] Thiel RJ. Growth effects of Warner protocol for children with Down syndrome. J Orthomol Med, in press 2002
[59] Thiel RJ. Facial effects of Warner protocol for children with Down syndrome. J Orthomol Med, in press 2002
[60] Dwyer J. Fertile fields for fads and frauds: questionable nutritional therapies. NY State J Med, 1993:105-108
[61] Barness LA, Dallman PR, Anderson H, Collipp PJ, Nichols BL, Walker WA, Woodruff CW. Megavitamins and mental retardation. American Academy of Pediatrics Policy Statement, August 1981
[62] Luke A, Sutton M, Schoeller DA, Roizen NJ. Nutrient intake and obesity in prepubescent children with Down syndrome. J Am Diet Assoc,1996;96(12):1262-1267
[63] Reading CM. Down's syndrome: nutritional interventions. Nutr Health, 1984;3(1-2):91-111
[64] Harrell RF, Capp RH, Davis DR, Peerless J, Ravitz LR. Can nutritional supplementation help mentally retarded children? An exploratory study. Proc Natl Acad Sci U S A,1981;78(1):574-578
[65] Weathers C. Effects of nutritional supplementation on IQ and certain other variables associated with Down syndrome. Am J Ment Defic, 1983;88(2):214-217
[66] Rimland B. Vitamin and mineral supplementation as a treatment for autistic and mentally retarded persons. Presentation to the President's Committee on Mental Retardation, Washington (D.C.), September 20, 1984
[67] Prasher VP. Down syndrome and thyroid disorders: a review. Downs Syndr Res Pract, 1999;6(1):25-42
[68] Karlsson B, et al. Thyroid dysfunction in Down's syndrome: relation to age and thyroid antibody. Arch Dis Childhood 1998;79:242-245
[69] Hetzel BS, Clugston GA. Iodine. In Modern Nutrition in Health and Disease, 9th ed. Williams & Wilkins, Balt., 1999:253-264
[70] Guyton AC, Hall JE. Textbook of Medical Physiology, 9th ed. WB Saunders, Phil.,1996
[71] Kanavin OJ, Aaseth J, Birketvedt GS. Thyroid hypofunction in Down's syndrome: is it related to oxidative stress? Biol Trace Elem Res 2000;78(1-3):35-42
[72] Pietz J. Neurological aspects of adult phenylketonuria. Curr Opin Neurol 1998;11(6):679-688
[73] Marsh RW, Cabaret JJ. Down's syndrome treated with a low phenylalanine diet: case report. N Z Med J 1972;75(481):364-365
[74] Becker W, Joost HG. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog Nucleic Acid Mol Biol 1999;62:1-17
[75] Kentrup H, Joost HG, Heimann G, Becker W. Midbrain/DYRK1A gene: a candidate for mental retardation in Down syndrome? Klin Padiatr 2000;212(2):60-63
[76] Himpel S, Panxer P, Eirmbter K, Czajkowska H, Sayed M, Packman L, Blundell T, Kentrup H, Grotzinger J, Joost HG, Becker W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J 2001;359(Pt3):497-505
[77] Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiat,1991;48:1097-1106
[78] Jovanovic SV, Clements D, MacLeod K. Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic Biol Med,1998;25(9):1044-1048
[79] Warner FJ, Stephens C. Metabolic supplementation for correction of raging free radicals in trisomy 21. Presentation at the International Down's Conference. Madrid, Spain, 1997
[80] Murray M, Pizzorno J. Alzheimer's disease. In Encyclopedia of Natural Medicine. Prima Publishing, Rocklin (CA), 1991:128-135
[81] Kohen R, Misgav R, Ginsburg I. The SOD like activity of copper: carnosine, copper: anserine copper: homocarnosine complexes. Free Radic Res Commun 1991;12-13, pt1:179-185
[82] Choi SY, Kwon HY, Kwon OB, Kang JH. Hydrogen peroxide-mediated Cu,ZN-superoxide dismutase fragmentation: protection by carnosine, homocarnosine and anserine. Biochim Biophys Acta 1999;1472(3):651-657
[83] Kang JH, Eum WS. Enhanced oxidative damage by the familial amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutants. Biochim Biophys Acta 2000;1524(2-3):162-170
[84] Odetti P, Angelini G, Dapino D, Zaccheo D, Garibaldi S, Dagna-Brica F, Piomba G, Perry G, Smith M, Traverso N, Tabaton M. Early glycation damage in the brains from Down's syndrome. Biochem Biophys Res Commun 1998;243(3):849-851
[85] Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med 2000;28(10):1564-1570
[86] Seidler NW. Carnosine prevents glycation-induced changes in electrophoretic of aspartate aminotransferase. J Biochem Mol Toxicol 2000;14(4):215-220
[87] Vinson J, Howard TB. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other nutrients. Nutr Biochem 1996;7:659-663
[88] De Falco FA, D'Angelo E, Grimaldi G, Scafuro F, Sachez F, Caruso G. Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome. Clin Ter 1994;144(2):123-127
[89] Laryea MD, Steinhagen F, Pawliczek S, Wendel U. Simple method for the routine determination of betaine and N,N-dimethylglycine in blood and urine. Clin Chem,1998;44(9):1937-1941
[90] Kendall RV, Lawson JW. Recent findings on N,N-dimethylglycine (DMG): a nutrient for the new millenium. Townsend Letter,2000;202:75-85
[91] Hamilton K. Nutritional aspects of children with Down syndrome. In Clinical Pearls 1999. ITServices, Sacramento, 1999:256
[92] Storm W. Prevalence and diagnostic significance of gliaden antibodies in children with Down's syndrome. Eur J Ped, 1990;149:833-834
[93] Dorfman K. Exploring the casein-free, gluten-free diet. New Developments;1(2):4
[94] Fuchtenbusch M, Karges W, Standl E, Dosch HM, Ziegler AG. Antibodies to bovine serum albumin in type 1 diabetes and other autoimmune disorders. Exp Clin Endocrinol Diabetes,1997;105(2):86-91
Source: | |
http://www.healthresearch.com/orthods.htm | Revised: March 20, 2003. |